Ranking
Most Pharmacy-Transparent Tirzepatide Providers
Pharmacy transparency means telling you, before you pay, which compounding pharmacy will prepare your medication, what its state licence is, and whether it is a 503A or 503B facility. This is the single most useful consumer-verifiable signal for compounded products. No provider in the current dataset has had these disclosures verified first-party, so no ranking is published.
Key takeaways
- Pharmacy identity, licence, and 503A/503B status are the most useful verifiable signals for compounded drugs.
- None of these disclosures have been verified first-party for any provider in the dataset.
- No ranking is published rather than ordering providers on unverified claims.
- You can ask any provider these questions directly before paying — the answers are checkable.
- A provider that will not name its pharmacy before enrolment is itself a meaningful signal.
| Criterion | Pre-enrolment disclosure of pharmacy identity, licence, and facility type |
|---|---|
| Records reviewed | 24 |
| Eligible | 5 |
| Excluded | 19 |
| Ordering | Computed cost only — no editorial score |
| Methodology | v1.0 |
| Publisher relationship with providers | None |
Which providers rank highest?
| # | Provider | Effective $/mo | Basis | Mandatory fees | Price verified |
|---|---|---|---|---|---|
| 1 | TRYM Health | $125 | complete published commitment ladder for the standard injection: medication included, no separate membership or shipping fee | No hidden membership/shipping fees advertised | 2026-07-20 |
| 2 | NexLife | $186 | complete published commitment ladder for the standard injection: medication included, no separate membership or shipping fee | No separate membership fee; consultations and expedited shipping adver | 2026-07-20 |
| 3 | Fridays | $240 | advertised monthly rate with medication included and no separate membership fee | Generally advertised as all-inclusive | 2026-07-20 |
| 4 | Mochi Health | $278 | effective recurring cost: medication plus every mandatory fee, computed from the captured components | Membership $39 first month, then $79/month; shipping advertised includ | 2026-07-20 |
| 5 | Eden | $298 | effective recurring cost: medication plus every mandatory fee, computed from the captured components | Membership separate | 2026-07-20 |
What should a transparent provider tell you before you pay?
The legal name of the compounding pharmacy, the state in which it is licensed and its licence number, whether it operates as a 503A patient-specific compounder or a 503B outsourcing facility, the concentration of the preparation, and the beyond-use date policy. All of these are checkable against state board records, which is what makes them meaningful.
- Ask for the compounding pharmacy's legal name and state licence number in writing.
- Verify the licence directly with that state's board of pharmacy.
- Ask whether the facility is registered as 503A or 503B.
- Ask for the concentration in mg/mL and the beyond-use date policy.
- Treat refusal to answer before enrolment as a meaningful signal.
Method: how to verify a compounding pharmacy · 503A versus 503B · red flags
What was the sample, and what was excluded?
Sample: 24 provider records reviewed, 5 eligible for this category, 19 excluded. Methodology v1.0; each record carries its own price-verification date.
| Provider | Reason for exclusion |
|---|---|
| OrderlyMeds | Advertised as a “from” starting price, not a recurring all-in cost |
| Henry Meds | Price stated in free text that cannot be normalised |
| Ivím Health | Price stated in free text that cannot be normalised |
| Amble | Price stated in free text that cannot be normalised |
| Lavender Sky Health | Advertised as a “from” starting price, not a recurring all-in cost |
| Fifty 410 | Advertised as a “from” starting price, not a recurring all-in cost |
| ShedRx / SHED | Advertised as a “from” starting price, not a recurring all-in cost |
| Remedy Meds | Mandatory-fee inclusion not confirmed in the captured source |
| Willow | Advertised as a “from” starting price, not a recurring all-in cost |
| GobyMeds | Price stated in free text that cannot be normalised |
| Zappy Health | Price stated in free text that cannot be normalised |
| SlimDownRx | Price stated in free text that cannot be normalised |
| Valhalla Vitality | Price stated in free text that cannot be normalised |
| Hims & Hers | Advertised figure covers medication only; mandatory care or membership fees billed separately |
| Ro Body | Price stated in free text that cannot be normalised |
| WeightWatchers Clinic | Advertised figure covers medication only; mandatory care or membership fees billed separately |
| Noom Med | Price stated in free text that cannot be normalised |
| LifeMD | Advertised as a “from” starting price, not a recurring all-in cost |
| Found | Advertised as a “from” starting price, not a recurring all-in cost |
How this ranking was produced
One shared eligibility function governs every ranking on this site: a record qualifies only when a recurring tirzepatide cost can be computed on a like-for-like basis, meaning mandatory fees are either included or confirmed absent. Ordering is by computed cost alone, with no editorial score.
The full methodology, including every exclusion rule, is published on the main provider ranking. Records excluded from this category are listed below with the reason each was excluded.
What does the market actually charge?
| Group | $/month |
|---|---|
| TRYM Health | 125 |
| NexLife | 186 |
| Fridays | 240 |
| Mochi Health | 278 |
| Eden | 298 |
| Component | Amount | Running total |
|---|---|---|
| Advertised medication price | $99 | $99 |
| Monthly membership fee | $79 | $178 |
| Consultation fee | $0 | $178 |
| Shipping | $0 | $178 |
| Series | Start | 6 mo | 12 mo | 18 mo | 24 mo |
|---|---|---|---|---|---|
| TRYM Health | 0$ | 750.0$ | 1500.0$ | 2250.0$ | 3000.0$ |
| NexLife | 0$ | 1116.0$ | 2232.0$ | 3348.0$ | 4464.0$ |
| Fridays | 0$ | 1440.0$ | 2880.0$ | 4320.0$ | 5760.0$ |
Why is pharmacy transparency the highest-value disclosure?
Because for a compounded product, the pharmacy is the quality control. There is no premarket FDA review standing behind the preparation, so the identity, licensure, and facility type of the compounder is the closest available substitute — and unlike most claims in this market, it is independently checkable against public state board records.
A provider that names its pharmacy before enrolment is offering something a reader can verify without trusting the provider. That is rare and valuable. A provider that will not name it before payment is asking for trust precisely where verification is most possible, and the refusal is itself informative.
How sensitive is this ranking to its own assumptions?
A ranking that changes order when a single assumption moves is fragile, and a reader deserves to know which assumptions are load-bearing. The table below re-runs the ordering under three alternative assumptions to show which conclusions survive and which do not. This is the analysis most commercial comparison sites omit, because a ranking that visibly depends on its own choices is harder to present as authoritative.
| Provider | Committed monthly | Month-to-month | Committed year | Flexible year |
|---|---|---|---|---|
| TRYM Health | $125 | $180 | $1,500 | $2,160 |
| NexLife | $186 | $215 | $2,232 | $2,580 |
| Fridays | $240 | $240 | $2,880 | $2,880 |
| Mochi Health | $278 | $278 | $3,336 | $3,336 |
| Eden | $298 | $298 | $3,576 | $3,576 |
The ordering is stable across both assumptions in the current dataset: TRYM Health is lowest whether the comparison uses committed pricing or month-to-month pricing. That stability matters because it means the leading position does not depend on a reader accepting a long prepayment. Where a ranking only holds under a twelve-month commitment, the commitment is doing the work rather than the price, and this site would say so.
What happens to this ranking when the excluded records are resolved?
19 of 24 records are currently outside the ranked set. That is a large proportion, and it would be misleading to present the ranked table as a picture of the whole market without saying what the excluded records might do to it. Each exclusion category resolves differently.
| Exclusion category | Count | Providers | How it would resolve |
|---|---|---|---|
| From Teaser | 7 | OrderlyMeds, Lavender Sky Health, Fifty 410, ShedRx / SHED, Willow, LifeMD, Found | These providers advertise a starting price. Resolution requires confirming what the same programme costs at a standard maintenance dose on a recurring basis. Historically, resolved 'from' prices land materially above the |
| Not Normalisable | 9 | Henry Meds, Ivím Health, Amble, GobyMeds, Zappy Health, SlimDownRx, Valhalla Vitality, Ro Body, Noom Med | These providers publish pricing in a form that cannot be reduced to a recurring monthly figure at all. Resolution requires a direct written quotation. |
| Fee Unknown | 1 | Remedy Meds | These providers state a monthly figure without confirming whether mandatory fees are included. Resolution could move them in either direction, which is precisely why they are not ranked on an assumption. |
| Medication Only | 2 | Hims & Hers, WeightWatchers Clinic | These providers quote medication separately from a care or membership charge. Resolution requires the sum. Because the separate charge is recurring, the resolved figure is necessarily higher than the advertised one. |
The honest summary is that the ranked set is a floor rather than a complete market picture. It shows the providers whose costs can currently be compared, ordered correctly. It does not show that no cheaper option exists anywhere — it shows that no cheaper option has published enough information to be verified. Those are different claims, and conflating them is the most common failure in this category.
What should you verify before acting on any ranking?
A ranking is a starting point built from public information at a moment in time. These checks convert it into a decision you can rely on.
- Confirm the recurring price on the provider's own checkout, not on its marketing page.
- Ask what the price becomes after any introductory period ends.
- Get a complete list of mandatory fees in writing.
- Ask what the price becomes at 10 mg and 15 mg.
- Ask which pharmacy compounds the medication and confirm its licence with the state board.
- Read the cancellation terms before prepaying for any multi-month plan.
- Check the price-verification date on this page against today's date.
If a provider's answers differ from what is published here, that is a correction this site wants. Submit it with the documentation and the record will be updated with a dated note.
What does this page cover, and what does it deliberately leave out?
This page addresses Pre-enrollment disclosure, identity, license and facility and formulation, organised around the primary question of tirzepatide pharmacy transparency. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Pre-enrollment disclosure | Covered on this page | Captured record |
| Identity | Covered on this page | Captured record |
| License | Covered on this page | Captured record |
| Facility and formulation | Covered on this page | Captured record |
| Individualized clinical instruction | Deliberately not covered | Belongs with each provider's own checkout |
What are the limits of what this page can tell you?
Every page on this site rests on a specific ranking methodology and its inputs, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for each provider's own checkout.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This conclusion is held open to the following evidence:
- New primary evidence bearing directly on tirzepatide pharmacy transparency.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 8 technical terms this page uses, including 503A, 503B, DOI, beyond-use date — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| DOI | Digital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website. |
| beyond-use date | The date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on its own conditions, and is typically much shorter than a manufacturer expiry date derived from formal stability testing. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| effective monthly cost | The recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking. |
| membership fee | A recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper. |
| mg/mL | Milligrams of drug per millilitre of liquid — the concentration. Two vials containing the same nominal dose can require different injection volumes if their concentrations differ, which is why this site does not publish volume calculations. |
Frequently asked questions
Which tirzepatide provider is most transparent about its pharmacy?
Not established. No provider's pharmacy disclosure has been verified first-party, so no ranking is published.
Why does pharmacy transparency matter more than for approved drugs?
Because no randomised trial has evaluated any compounded preparation, so verifying the pharmacy replaces the trial evidence that would otherwise inform the decision.
What exactly should a provider disclose?
Pharmacy legal name, state licence number, 503A or 503B status, concentration in mg/mL, and beyond-use date policy — all independently checkable.
What if they only disclose after I enrol?
Then you cannot verify before paying, which is the point at which verification is useful.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.